The FDA-cleared, non-invasive medical device—VivoScore, developed by Vivos Therapeutics by leveraging proprietary Cardiopulmonary Coupling (CPC) technology—is revolutionizing the diagnosis of Obstructive Sleep Apnea (OSA) in clinical practice.
This Bluetooth-enabled ring delivers clinical-grade sleep diagnostics at a fraction of the cost of traditional polysomnography, making diagnostics accessible for healthcare providers at under $50 per test. It is also suitable for patients as young as 2 years old, significantly widening its clinical application.
This is critically important since OSA, affecting up to 80 million U.S. adults, is linked to severe health risks, including cardiovascular disease, stroke, diabetes, and even cancer.
DocWire News spoke with Kirk Huntsman, Chairman & CEO of Vivos Therapeutics, about the company and how Vivos is helping to advance care in the sleep medicine space.